Novartis targets oncologists with blog

Share this article:
Novartis is experimenting with blogging for physicians with melanomaperspectives.com.
Executed by Compass Healthcare Communications, it went live in August with a panel of five knowledge and opinion leader contributors.

Though the site is unbranded, Novartis hopes to educate referring and community oncologists about the benefits of interleukin-2 therapies like the company's Proleukin, for metastatic melanoma and metastatic kidney cancer. A late-stage treatment, Proleukin suffers from a lack of awareness regarding the timing and usage of immunotherapy versus chemotherapy.

As the site does not have comments, Novartis doesn't have to worry about the thorny issue of adverse events reporting. All content is reviewed by the company for medical, regulatory and legal correctness before posting. It will be supported by search engine optimization, details and banner ads.  

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...